@article{article, title  = {{Vedolizumab for Treating Moderately to Severely Active Crohn’s Disease After Prior Therapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal}},

 url = {{http://eprints.whiterose.ac.uk/106724/ }},

 year = {{2016}},

 month = {{8}},

 author = {{Rafia R and Scope A and Harnan S and Stevens JW and Stevenson M and Lobo A}},

 doi = {{10.1007/s40273-016-0436-6}},

 volume = {{34}},

 journal = {{PharmacoEconomics}},

 issue = {{12}},

 pages = {{1241-1253}},

 note = {{Accessed on 2024/12/21}}}